225 related articles for article (PubMed ID: 16728940)
1. Myeloma and bone disease: "the dangerous tango".
Epstein J; Walker R
Clin Adv Hematol Oncol; 2006 Apr; 4(4):300-6. PubMed ID: 16728940
[TBL] [Abstract][Full Text] [Related]
2. Myeloma bone disease: recent advances in biology, diagnosis, and treatment.
Sezer O
Oncologist; 2009 Mar; 14(3):276-83. PubMed ID: 19286761
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of myeloma bone disease.
Roodman GD
Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis of myeloma bone disease.
Roodman GD
J Cell Biochem; 2010 Feb; 109(2):283-91. PubMed ID: 20014067
[TBL] [Abstract][Full Text] [Related]
5. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
[TBL] [Abstract][Full Text] [Related]
6. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.
Andersen TL; Søe K; Sondergaard TE; Plesner T; Delaisse JM
Br J Haematol; 2010 Feb; 148(4):551-61. PubMed ID: 19919653
[TBL] [Abstract][Full Text] [Related]
7. Bone markers in multiple myeloma.
Heider U; Fleissner C; Zavrski I; Kaiser M; Hecht M; Jakob C; Sezer O
Eur J Cancer; 2006 Jul; 42(11):1544-53. PubMed ID: 16765040
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
9. Vertebral augmentation in osteoporosis and bone metastasis.
Siemionow K; Lieberman IH
Curr Opin Support Palliat Care; 2007 Dec; 1(4):323-7. PubMed ID: 18685383
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology of multiple myeloma bone disease.
Lentzsch S; Ehrlich LA; Roodman GD
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
[TBL] [Abstract][Full Text] [Related]
11. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?
Silvestris F; Ciavarella S; De Matteo M; Tucci M; Dammacco F
Oncologist; 2009 Mar; 14(3):264-75. PubMed ID: 19286760
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis and management of myeloma bone disease.
Christoulas D; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
[TBL] [Abstract][Full Text] [Related]
13. Role of osteoblast suppression in multiple myeloma.
Stewart JP; Shaughnessy JD
J Cell Biochem; 2006 May; 98(1):1-13. PubMed ID: 16440324
[TBL] [Abstract][Full Text] [Related]
14. Management of complications in multiple myeloma.
Terpos E; Cibeira MT; Blade J; Ludwig H
Semin Hematol; 2009 Apr; 46(2):176-89. PubMed ID: 19389501
[TBL] [Abstract][Full Text] [Related]
15. Osteoblasts suppress high bone turnover caused by osteolytic breast cancer in-vitro.
Krawetz R; Wu YE; Rancourt DE; Matyas J
Exp Cell Res; 2009 Aug; 315(14):2333-42. PubMed ID: 19433087
[TBL] [Abstract][Full Text] [Related]
16. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
17. Advances in the biology and treatment of bone disease in multiple myeloma.
Raje N; Roodman GD
Clin Cancer Res; 2011 Mar; 17(6):1278-86. PubMed ID: 21411443
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
Giuliani N; Rizzoli V; Roodman GD
Blood; 2006 Dec; 108(13):3992-6. PubMed ID: 16917004
[TBL] [Abstract][Full Text] [Related]
19. [Management of multiple myeloma-related bone disease].
Jurczyszyn A; Grosicki S; Czerniuk MR; Morga R; Małecki K; Skotnicki AB
Przegl Lek; 2013; 70(11):950-7. PubMed ID: 24697037
[TBL] [Abstract][Full Text] [Related]
20. Myeloma bone disease and treatment options.
Yeh HS; Berenson JR
Eur J Cancer; 2006 Jul; 42(11):1554-63. PubMed ID: 16797971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]